EG245651 Inhibitors
EG245651 inhibitors represent a specific class of chemical compounds that are designed to target and modulate the activity of a protein or enzyme referred to as EG245651. While the exact structural characteristics of these inhibitors can vary, they typically share a common pharmacophore that is essential for binding to the active or allosteric sites of the target protein. This binding is often achieved through a combination of non-covalent interactions, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. The molecular architecture of EG245651 inhibitors is crafted to ensure high affinity and selectivity towards their target, minimizing interactions with other proteins and reducing off-target effects. Additionally, these compounds are usually optimized for stability, solubility, and membrane permeability, ensuring effective engagement with the target protein in various biological environments.
Research into EG245651 inhibitors involves understanding the conformational dynamics of the target protein, as well as the kinetic and thermodynamic properties that govern inhibitor binding. Structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are often employed to elucidate the binding modes of these inhibitors at atomic resolution. Computational modeling and molecular dynamics simulations also play a crucial role in predicting the interaction patterns and in optimizing the chemical structures of the inhibitors for enhanced efficacy and specificity. Further studies may involve biochemical assays to determine the potency of these inhibitors in modulating the activity of EG245651 and to assess their effects on various downstream signaling pathways and cellular processes. The development of EG245651 inhibitors is a significant area of chemical biology, contributing to the broader understanding of protein function and regulation within complex biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, disrupts the MAPK pathway. By inhibiting MEK, it indirectly influences Gm4995 expression and function through altered intracellular signaling cascades, impacting the regulatory mechanisms associated with the MAPK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that affects the PI3K/AKT pathway. Its inhibition disrupts downstream signaling, indirectly influencing Gm4995 by altering cellular processes connected to PI3K/AKT, potentially affecting its expression and function through perturbed intracellular signaling. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a bromodomain inhibitor, disrupts BET proteins' interaction with chromatin. As Gm4995 may be regulated epigenetically, JQ1's impact on chromatin accessibility indirectly influences Gm4995 expression, potentially modulating its function through altered transcriptional regulation mechanisms. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, disrupting downstream signaling. As Gm4995 may be influenced by NF-κB, its inhibition can indirectly affect Gm4995 expression and function by altering the transcriptional regulation mediated by NF-κB in various cellular contexts. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 inhibits GSK-3, influencing the Wnt pathway. Given the interconnected nature of cellular pathways, its impact on Wnt signaling indirectly affects Gm4995. This may lead to altered expression and function of Gm4995 through perturbed signaling cascades associated with Wnt pathway modulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By targeting p38 MAPK, it influences the MAPK signaling pathway. This indirect inhibition may impact Gm4995, as the MAPK pathway is interconnected with various cellular processes, potentially affecting its expression and function through altered signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cellular processes. By influencing mTOR signaling, it indirectly impacts Gm4995, potentially altering its expression and function through disrupted intracellular signaling pathways related to mTOR-mediated cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a member of the MAPK family. Its impact on the MAPK pathway indirectly influences Gm4995, potentially affecting its expression and function through altered signaling cascades associated with JNK-mediated cellular responses. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
AZD2014 is an mTOR inhibitor that affects the mTOR signaling pathway. Its inhibition disrupts downstream signaling, indirectly influencing Gm4995 by potentially altering the mTOR pathway. This impact may result in changes to Gm4995 expression and function through perturbed intracellular signaling. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces DNA damage, affecting cellular processes. Indirectly, this can impact Gm4995 by disrupting cellular homeostasis, potentially influencing its expression and function through altered regulatory mechanisms related to DNA damage response pathways. | ||||||